Related Experiment Videos
Inotropic agents and immune modulation
1Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan. sasayama@wonder.ocn.ne.jp
Insights
Phosphodiesterase inhibitors may benefit Japanese heart failure patients, unlike other inotropic agents. These agents show potential for symptom relief and improved quality of life, possibly due to their immunomodulating effects.
Area of Science:
- Cardiology
- Pharmacology
- Immunology
Background:
- Myocardial contractility depression is central to heart failure development.
- Previous studies in Western societies linked long-term inotropic agent use to increased mortality.
- This suggests traditional inotropic agents are unsuitable for chronic heart failure management.
Discussion:
- Certain phosphodiesterase inhibitors show promise in Japanese heart failure patients.
- Japan's lower heart disease mortality may influence treatment outcomes.
- These agents may offer symptom relief and enhance quality of life.
Key Insights:
- Phosphodiesterase inhibitors possess cardiotonic, anticytokine, and immunomodulating properties.
- Cytokine-mediated immune responses are implicated in heart failure pathogenesis.
- These findings support a new paradigm in heart failure treatment.
Outlook:
- Further research into phosphodiesterase inhibitors for chronic heart failure is warranted.
- Investigating the immunomodulatory mechanisms could reveal novel therapeutic targets.
- Tailoring treatments based on regional differences in heart disease mortality may be beneficial.
Abstract:
Since depression of myocardial contractility forms the basis for the development of heart failure, many attempts have been made to enhance the inotropic state of the failing heart by cardiotonic agent as the therapeutic modality. However, large scale clinical trials conducted in the Western societies revealed excess mortality in patients with heart failure received long-term treatment with inotropic agent. Therefore, all of these agents are now regarded as unsuitable for chronic heart failure treatment. In contrast, some inotropic agents with phosphodiesterase inhibitory properties exhibited potential benefits in Japanese patients. In Japan mortality due to heart disease is substantially lower than that found in all other Western countries. Thereby, chronic treatment with inotropic agent may be justified as the optimal care in the context of relief of symptoms and an improved quality of life. The salutary effects of these phosphodiesterase inhibitors appear to be related to anticytokine and immunomodulating effects as well as their cardiotonic action. These findings support the recent new concept that immune responses mediated by cytokines play an important role in the pathogenesis of heart failure.